Neurocrine Biosciences (NBIX) Financials

$122.64 +2.46 (+2.05%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$122.64 +0.00 (+0.00%)

As of 05/27/2025 04:28 PM Eastern

Annual Income Statements for Neurocrine Biosciences

This table shows Neurocrine Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	341	250	155	90	407	37	21	-143	-141	-89
Consolidated Net Income / (Loss)	341	250	155	90	407	37	21	-143	-141	-89
Net Income / (Loss) Continuing Operations	341	250	155	90	407	37	21	-143	-141	-89
Total Pre-Tax Income	486	332	214	101	107	47	22	-143	-141	-89
Total Operating Income	571	251	249	103	163	72	37	-131	-147	-94
Total Gross Profit	2,321	1,847	1,466	1,119	1,036	781	446	160	15	20
Total Revenue	2,355	1,887	1,489	1,134	1,046	788	451	162	15	20
Operating Revenue	2,355	1,887	1,489	1,134	1,046	788	451	162	15	20
Total Cost of Revenue	34	40	23	14	10	7.40	4.90	1.25	0.00	0.00
Operating Cost of Revenue	34	40	23	14	10	7.40	4.90	1.25	0.00	0.00
Total Operating Expenses	1,751	1,597	1,217	1,017	873	708	410	292	162	114
Selling, General & Admin Expense	1,007	888	753	583	433	354	249	170	68	32
Research & Development Expense	744	709	464	433	440	354	161	122	94	81
Total Other Income / (Expense), net	-85	81	-35	-1.10	-56	-26	-15	-11	6.28	5.27
Interest Expense	138	0.00	70	26	51	32	31	20	0.00	0.00
Interest & Investment Income	91	53	4.10	3.80	13	19	16	8.34	6.28	1.93
Other Income / (Expense), net	-37	28	31	21	-18	-13	0.00	0.00	-	3.35
Income Tax Expense	145	82	59	12	-301	9.50	0.70	-	0.00	-
Basic Earnings per Share	$3.40	$2.56	$1.61	$0.95	$4.38	$0.40	$0.23	($1.62)	($1.63)	($1.05)
Weighted Average Basic Shares Outstanding	100.40M	97.70M	95.80M	94.60M	93.10M	91.60M	90.20M	88.09M	86.71M	84.50M
Diluted Earnings per Share	$3.29	$2.47	$1.56	$0.92	$4.16	$0.39	$0.22	($1.62)	($1.63)	($1.05)
Weighted Average Diluted Shares Outstanding	103.70M	101M	98.90M	97.90M	97.80M	95.70M	95.40M	88.09M	86.71M	84.50M
Weighted Average Basic & Diluted Shares Outstanding	99.70M	99.51M	96.59M	95.24M	93.94M	92.50M	91.80M	88M	86.60M	84.70M

This table shows Neurocrine Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	7.90	103	130	65	43	148	83	96	-77	89	69
Consolidated Net Income / (Loss)	7.90	103	130	65	43	148	83	96	-77	89	69
Net Income / (Loss) Continuing Operations	7.90	103	130	65	43	148	83	96	-77	89	69
Total Pre-Tax Income	15	163	190	99	35	198	116	122	-103	118	98
Total Operating Income	24	142	184	145	99	150	141	74	-114	103	88
Total Gross Profit	563	618	614	581	508	507	488	441	412	404	382
Total Revenue	573	628	622	590	515	515	499	453	420	412	388
Operating Revenue	573	628	622	590	515	515	499	453	420	412	388
Total Cost of Revenue	9.20	9.30	8.00	9.20	7.50	8.50	11	12	8.50	7.70	6.10
Operating Cost of Revenue	9.20	9.30	8.00	9.20	7.50	8.50	11	12	8.50	7.70	6.10
Total Operating Expenses	540	476	430	436	409	356	346	368	526	301	294
Selling, General & Admin Expense	277	288	234	242	243	219	204	222	243	183	186
Research & Development Expense	263	189	196	194	165	138	142	146	283	118	108
Total Other Income / (Expense), net	-8.90	21	6.50	-47	-65	48	-26	48	11	15	10
Interest Expense	0.00	88	0.00	50	1.10	-1.10	0.00	0.00	1.10	-6.00	1.20
Interest & Investment Income	22	21	23	23	23	18	15	11	9.80	1.30	0.20
Other Income / (Expense), net	-31	87	-17	-20	-87	29	-40	37	2.20	7.20	11
Income Tax Expense	6.80	60	61	34	-8.90	51	33	26	-27	29	29
Basic Earnings per Share	$0.08	$1.05	$1.28	$0.64	$0.43	$1.52	$0.85	$0.98	($0.79)	$0.92	$0.72
Weighted Average Basic Shares Outstanding	99.70M	100.40M	101.10M	100.80M	99.80M	97.70M	97.90M	97.60M	97.10M	95.80M	95.80M
Diluted Earnings per Share	$0.08	$1.00	$1.24	$0.63	$0.42	$1.49	$0.82	$0.95	($0.79)	$0.91	$0.69
Weighted Average Diluted Shares Outstanding	102.50M	103.70M	104.30M	103.90M	103.60M	101M	101.10M	100.20M	97.10M	98.90M	99M
Weighted Average Basic & Diluted Shares Outstanding	98.97M	99.70M	101.25M	100.98M	100.64M	99.51M	98.25M	97.65M	97.57M	96.59M	96.13M

This table details how cash moves in and out of Neurocrine Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-18	-12	-73	154	75	-32	-112	171	9.16	43
Net Cash From Operating Activities	595	390	339	257	229	147	101	-94	-106	-38
Net Cash From Continuing Operating Activities	595	390	339	257	229	147	101	-94	-106	-38
Net Income / (Loss) Continuing Operations	341	250	155	90	407	37	21	-143	-141	-89
Consolidated Net Income / (Loss)	341	250	155	90	407	37	21	-143	-141	-89
Depreciation Expense	24	18	15	11	8.60	7.40	4.00	2.40	1.45	1.01
Amortization Expense	-23	-15	4.20	25	21	20	19	14	3.52	6.03
Non-Cash Adjustments To Reconcile Net Income	371	166	212	113	136	88	58	43	24	25
Changes in Operating Assets and Liabilities, net	-118	-29	-47	18	-345	-6.00	-0.70	-10	5.49	19
Net Cash From Investing Activities	-127	-467	-177	-130	4.10	-211	-243	-251	113	-196
Net Cash From Continuing Investing Activities	-127	-467	-177	-130	4.10	-211	-243	-251	113	-196
Purchase of Property, Plant & Equipment	-38	-28	-17	-23	-11	-15	-25	-6.94	-4.11	-1.93
Acquisitions	0.00	0.00	-43	0.00	0.00	-	-	-	-	-
Purchase of Investments	-1,056	-1,411	-629	-805	-736	-866	-546	-583	-299	-449
Sale and/or Maturity of Investments	968	972	511	698	751	670	328	339	416	255
Net Cash From Financing Activities	-487	65	-234	27	-158	32	30	517	2.39	277
Net Cash From Continuing Financing Activities	-487	65	-234	27	-158	32	30	517	2.39	277
Repayment of Debt	-309	0.00	-279	-0.10	-187	0.00	0.00	-	-	-
Repurchase of Common Equity	-300	0.00	0.00	-	-	-	-	-	-	-
Issuance of Common Equity	122	65	45	28	29	32	30	14	2.39	277
Effect of Exchange Rate Changes	0.00	0.30	-1.30	0.00	0.00	-	-	-	-	-
Cash Interest Paid	1.60	3.80	6.60	8.60	12	12	12	6.24	0.00	0.00
Cash Income Taxes Paid	218	52	14	5.10	15	0.50	0.00	0.00	-	0.00

This table details how cash moves in and out of Neurocrine Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-39	-116	209	-257	145	-43	134	57	-159	51	49
Net Cash From Operating Activities	65	243	158	65	130	124	212	180	-125	143	99
Net Cash From Continuing Operating Activities	65	243	158	65	130	124	212	180	-125	143	99
Net Income / (Loss) Continuing Operations	7.90	103	130	65	43	148	83	96	-77	89	69
Consolidated Net Income / (Loss)	7.90	103	130	65	43	148	83	96	-77	89	69
Depreciation Expense	6.60	6.20	5.60	6.40	5.30	4.90	4.60	4.20	4.10	3.90	4.00
Amortization Expense	-3.60	-4.70	-5.60	-6.10	-6.20	-5.50	-5.10	-3.00	-1.20	3.20	0.20
Non-Cash Adjustments To Reconcile Net Income	83	54	58	127	132	9.10	88	31	38	36	32
Changes in Operating Assets and Liabilities, net	-30	84	-30	-127	-44	-33	42	52	-89	11	-5.90
Net Cash From Investing Activities	14	-68	25	-28	-55	-202	-97	-126	-42	-116	-61
Net Cash From Continuing Investing Activities	14	-68	25	-28	-55	-202	-97	-126	-42	-116	-61
Purchase of Property, Plant & Equipment	-11	-7.30	-8.10	-12	-11	-5.40	-7.60	-6.80	-8.50	-1.80	1.70
Purchase of Investments	-273	-312	-233	-192	-320	-487	-363	-324	-238	-233	-134
Sale and/or Maturity of Investments	298	251	265	175	276	291	273	205	204	162	71
Net Cash From Financing Activities	-118	-290	26	-293	70	35	19	2.90	8.20	25	11
Net Cash From Continuing Financing Activities	-118	-290	26	-293	70	35	19	2.90	8.20	25	11
Repurchase of Common Equity	-150	-	-	-	-	-	-	-	-	-	-
Issuance of Common Equity	32	10	26	16	70	35	19	2.90	8.20	25	11
Cash Income Taxes Paid	0.60	73	52	93	0.20	47	1.60	3.20	0.20	10	1.20

This table presents Neurocrine Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	3,719	3,251	2,369	2,073	1,735	1,306	993	818	365	475
Total Current Assets	1,725	1,607	1,454	973	1,016	831	738	555	310	384
Cash & Equivalents	233	251	263	341	187	112	142	255	83	74
Short-Term Investments	843	781	726	371	614	558	509	261	224	305
Accounts Receivable	479	439	350	186	157	127	57	31	0.00	-
Inventories, net	57	38	35	31	28	17	11	1.02	-	-
Other Current Assets	112	98	79	46	30	17	19	6.84	3.09	4.88
Plant, Property, & Equipment, net	83	71	59	59	45	42	34	11	6.27	3.43
Total Noncurrent Assets	1,911	1,574	857	1,041	674	433	222	252	48	87
Long-Term Investments	864	849	299	624	265	356	216	247	43	82
Intangible Assets	37	36	37	0.00	-	-	-	-	-	-
Noncurrent Deferred & Refundable Income Taxes	486	363	306	315	319	0.00	-	-	-	-
Other Noncurrent Operating Assets	525	326	214	102	89	74	-	-	-	-
Total Liabilities & Shareholders' Equity	3,719	3,251	2,369	2,073	1,735	1,306	993	818	365	475
Total Liabilities	1,129	1,019	661	699	609	669	512	445	50	50
Total Current Liabilities	508	655	538	246	187	565	88	54	30	26
Short-Term Debt	0.00	170	169	0.00	-	409	-	-	-	-
Accounts Payable	462	449	348	226	169	141	86	54	26	2.56
Other Current Liabilities	46	36	21	20	18	15	1.86	0.91	0.24	0.43
Total Noncurrent Liabilities	621	365	123	453	422	104	424	391	20	25
Other Noncurrent Operating Liabilities	621	365	123	118	104	104	36	8.04	8.10	13
Total Equity & Noncontrolling Interests	2,590	2,232	1,708	1,374	1,126	637	481	372	315	424
Total Preferred & Common Equity	2,590	2,232	1,708	1,374	1,126	637	481	372	315	424
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,590	2,232	1,708	1,374	1,126	637	481	372	315	424
Common Stock	2,555	2,382	2,123	2,012	1,850	1,768	1,660	1,573	1,372	1,341
Retained Earnings	29	-157	-407	-636	-725	-1,133	-1,178	-1,199	-1,056	-915
Accumulated Other Comprehensive Income / (Loss)	5.80	7.00	-7.90	-1.70	1.80	1.40	-1.93	-1.85	-0.32	-0.98

This table presents Neurocrine Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	3,688	3,535	3,305	3,472	2,848	2,613	2,360	2,143
Total Current Assets	1,638	1,877	1,670	1,799	1,650	1,497	1,433	1,206
Cash & Equivalents	194	349	140	396	294	160	104	212
Short-Term Investments	749	879	899	814	801	817	791	587
Accounts Receivable	516	481	468	451	418	388	392	301
Inventories, net	59	46	43	37	29	32	33	37
Other Current Assets	119	122	120	101	108	101	113	68
Plant, Property, & Equipment, net	87	80	80	75	69	66	63	61
Total Noncurrent Assets	1,963	1,578	1,555	1,598	1,130	1,051	864	877
Long-Term Investments	910	771	638	864	455	343	245	363
Intangible Assets	36	35	34	34	35	37	37	-
Noncurrent Deferred & Refundable Income Taxes	499	454	420	378	383	379	337	319
Other Noncurrent Operating Assets	518	319	464	322	257	292	245	195
Total Liabilities & Shareholders' Equity	3,688	3,535	3,305	3,472	2,848	2,613	2,360	2,143
Total Liabilities	1,152	816	796	1,086	846	760	675	599
Total Current Liabilities	523	430	399	713	692	583	374	485
Accounts Payable	475	393	359	417	503	392	356	298
Other Current Liabilities	48	37	40	173	19	21	18	18
Total Noncurrent Liabilities	629	386	397	373	155	178	301	114
Other Noncurrent Operating Liabilities	629	386	397	373	155	178	132	114
Total Equity & Noncontrolling Interests	2,536	2,719	2,509	2,386	2,002	1,853	1,685	1,545
Total Preferred & Common Equity	2,536	2,719	2,509	2,386	2,002	1,853	1,685	1,545
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,536	2,719	2,509	2,386	2,002	1,853	1,685	1,545
Common Stock	2,532	2,623	2,555	2,497	2,309	2,242	2,171	2,054
Retained Earnings	-5.30	81	-49	-114	-305	-388	-483	-496
Accumulated Other Comprehensive Income / (Loss)	9.00	15	2.50	3.30	-1.70	-1.10	-2.70	-14

This table displays calculated financial ratios and metrics derived from Neurocrine Biosciences' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	24.81%	26.76%	31.34%	8.38%	32.71%	74.67%	179.16%	977.51%	-24.12%	0.00%
EBITDA Growth	89.27%	-5.62%	88.11%	-9.30%	101.49%	45.73%	151.72%	18.95%	-69.89%	-48.21%
EBIT Growth	90.98%	-0.18%	126.74%	-15.07%	145.03%	61.14%	128.01%	10.86%	-62.20%	-48.53%
NOPAT Growth	112.38%	4.89%	98.57%	-85.44%	981.56%	61.52%	138.74%	10.86%	-56.44%	-46.25%
Net Income Growth	36.68%	61.62%	72.43%	-78.00%	1,000.81%	75.36%	114.80%	-1.03%	-58.65%	-46.89%
EPS Growth	33.20%	58.33%	69.57%	-77.88%	966.67%	77.27%	113.58%	0.61%	-55.24%	-29.63%
Operating Cash Flow Growth	52.71%	14.88%	32.32%	12.25%	55.44%	44.97%	207.49%	11.16%	-179.45%	19.40%
Free Cash Flow Firm Growth	6.40%	826.43%	-137.11%	-63.59%	586.85%	198.02%	111.93%	-2.33%	-103.14%	-8.29%
Invested Capital Growth	24.60%	-11.45%	57.61%	-1.16%	2,203.66%	619.48%	87.87%	36.26%	2.78%	-53.16%
Revenue Q/Q Growth	5.02%	5.79%	7.20%	5.99%	0.36%	16.68%	8.92%	140.84%	0.00%	0.00%
EBITDA Q/Q Growth	10.53%	26.88%	58.84%	-29.58%	20.23%	48.75%	5.71%	35.32%	-16.43%	-12.84%
EBIT Q/Q Growth	10.23%	32.62%	73.47%	-37.55%	25.26%	78.08%	13.24%	30.66%	-14.73%	-12.73%
NOPAT Q/Q Growth	-6.44%	21.91%	132.41%	-84.83%	392.97%	27.06%	32.62%	30.66%	-11.76%	-12.25%
Net Income Q/Q Growth	-11.56%	30.73%	165.46%	-79.86%	336.08%	75.63%	112.55%	26.56%	-12.20%	-12.49%
EPS Q/Q Growth	-12.96%	30.69%	168.97%	-79.87%	320.20%	0.00%	0.00%	27.35%	-10.88%	-11.70%
Operating Cash Flow Q/Q Growth	24.98%	-4.76%	69.19%	-26.04%	-1.30%	47.01%	10.84%	43.36%	-18.30%	0.28%
Free Cash Flow Firm Q/Q Growth	-17.47%	203.58%	68.70%	-67.42%	118.33%	4,542.06%	49.76%	31.48%	-12.78%	-4.19%
Invested Capital Q/Q Growth	-9.86%	-16.25%	6.65%	3.21%	571.05%	-66.90%	-162.11%	-96.23%	-11.97%	-14.55%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.56%	97.90%	98.44%	98.74%	99.03%	99.06%	98.91%	99.22%	100.00%	100.00%
EBITDA Margin	22.69%	14.96%	20.09%	14.03%	16.76%	11.04%	13.23%	-71.41%	-949.33%	-423.98%
Operating Margin	24.22%	13.30%	16.73%	9.04%	15.58%	9.17%	8.16%	-81.27%	-982.48%	-476.51%
EBIT Margin	22.65%	14.80%	18.79%	10.89%	13.89%	7.52%	8.16%	-81.27%	-982.48%	-459.59%
Profit (Net Income) Margin	14.49%	13.23%	10.38%	7.90%	38.94%	4.69%	4.68%	-88.19%	-940.60%	-449.84%
Tax Burden Percent	70.23%	75.19%	72.23%	88.36%	381.72%	79.57%	96.79%	100.00%	100.00%	100.00%
Interest Burden Percent	91.11%	118.90%	76.45%	82.17%	73.43%	78.41%	59.24%	108.51%	95.74%	97.88%
Effective Tax Rate	29.77%	24.81%	27.77%	11.64%	-281.72%	20.43%	3.21%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	68.46%	34.00%	37.40%	24.11%	315.68%	868.82%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	71.71%	29.69%	39.79%	24.23%	347.08%	872.54%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-54.31%	-21.33%	-27.37%	-16.95%	-269.48%	-862.20%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	14.16%	12.68%	10.03%	7.17%	46.20%	6.62%	4.95%	-41.50%	-38.17%	-28.09%
Cash Return on Invested Capital (CROIC)	46.56%	46.15%	-7.33%	25.29%	132.32%	231.54%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	15.31%	9.94%	12.60%	6.48%	9.56%	5.16%	4.06%	-22.21%	-35.09%	-25.31%
Return on Assets (ROA)	9.79%	8.89%	6.96%	4.71%	26.79%	3.22%	2.33%	-24.11%	-33.60%	-24.78%
Return on Common Equity (ROCE)	14.16%	12.68%	10.03%	7.17%	46.20%	6.62%	4.95%	-41.50%	-38.17%	-28.09%
Return on Equity Simple (ROE_SIMPLE)	13.18%	11.19%	9.05%	6.52%	36.17%	5.81%	4.39%	-38.30%	-44.81%	-20.95%
Net Operating Profit after Tax (NOPAT)	401	189	180	91	622	58	36	-92	-103	-66
NOPAT Margin	17.01%	10.00%	12.08%	7.99%	59.49%	7.30%	7.89%	-56.89%	-687.74%	-333.56%
Net Nonoperating Expense Percent (NNEP)	-3.25%	4.31%	-2.39%	-0.11%	-31.40%	-3.72%	-3.29%	-13.42%	-9.23%	-6.54%
Return On Investment Capital (ROIC_SIMPLE)	15.47%	7.85%	9.58%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	1.44%	2.10%	1.56%	1.26%	0.97%	0.94%	1.09%	0.78%	0.00%	0.00%
SG&A Expenses to Revenue	42.76%	47.04%	50.56%	51.46%	41.43%	44.93%	55.16%	105.12%	453.87%	164.30%
R&D to Revenue	31.57%	37.57%	31.15%	38.24%	42.02%	44.96%	35.59%	75.38%	628.61%	412.22%
Operating Expenses to Revenue	74.33%	84.60%	81.72%	89.70%	83.45%	89.89%	90.76%	180.50%	1,082.48%	576.51%
Earnings before Interest and Taxes (EBIT)	533	279	280	123	145	59	37	-131	-147	-91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	534	282	299	159	175	87	60	-115	-142	-84
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.34	5.80	6.72	5.88	7.95	15.54	13.47	18.45	10.68	11.49
Price to Tangible Book Value (P/TBV)	5.41	5.89	6.87	5.88	7.95	15.54	13.47	18.45	10.68	11.49
Price to Revenue (P/Rev)	5.87	6.86	7.71	7.13	8.56	12.56	14.35	42.48	224.13	246.66
Price to Earnings (P/E)	40.49	51.84	74.32	90.18	21.99	267.54	306.90	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.47%	1.93%	1.35%	1.11%	4.55%	0.37%	0.33%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	18.30	21.56	17.61	18.96	21.72	565.97	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	5.04	5.95	6.96	6.25	7.85	11.78	13.29	40.05	200.74	223.30
Enterprise Value to EBITDA (EV/EBITDA)	22.23	39.80	34.65	44.52	46.82	106.69	100.46	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	22.27	40.22	37.04	57.37	56.48	156.52	162.97	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	29.65	59.55	57.62	78.16	13.19	161.34	168.37	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	19.95	28.81	30.53	27.60	35.92	63.14	59.14	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	43.61	43.88	0.00	74.54	31.47	244.44	470.69	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.08	0.10	0.24	0.28	0.64	0.81	0.99	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.24	0.28	0.00	0.81	0.99	0.00	0.00
Financial Leverage	-0.76	-0.72	-0.69	-0.70	-0.78	-0.99	-1.03	-1.10	-1.11	-1.11
Leverage Ratio	1.45	1.43	1.44	1.52	1.72	2.06	2.12	1.72	1.14	1.13
Compound Leverage Factor	1.32	1.70	1.10	1.25	1.27	1.61	1.26	1.87	1.09	1.11
Debt to Total Capital	0.00%	7.08%	9.02%	19.61%	22.01%	39.09%	44.69%	49.83%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	7.08%	9.02%	0.00%	0.00%	39.09%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	19.61%	22.01%	0.00%	44.69%	49.83%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	92.92%	90.98%	80.39%	77.99%	60.91%	55.31%	50.17%	100.00%	100.00%
Debt to EBITDA	0.00	0.60	0.57	2.11	1.81	4.70	6.51	-3.20	0.00	0.00
Net Debt to EBITDA	0.00	-6.06	-3.74	-6.29	-4.27	-7.10	-8.01	3.41	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	2.11	1.81	0.00	6.51	-3.20	0.00	0.00
Debt to NOPAT	0.00	0.90	0.94	3.70	0.51	7.11	10.91	-4.02	0.00	0.00
Net Debt to NOPAT	0.00	-9.07	-6.22	-11.05	-1.20	-10.73	-13.43	4.28	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	3.70	0.51	0.00	10.91	-4.02	0.00	0.00
Altman Z-Score	8.86	8.77	11.67	7.68	9.70	8.66	7.28	7.60	35.75	55.75
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.40	2.45	2.70	3.96	5.45	1.47	8.36	10.20	10.21	14.94
Quick Ratio	3.06	2.25	2.49	3.65	5.14	1.41	8.03	10.05	10.11	14.75
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	272	256	-35	95	261	38	13	-107	-104	-51
Operating Cash Flow to CapEx	1,558.64%	1,377.74%	2,056.97%	1,096.15%	2,096.33%	1,000.00%	408.87%	-1,360.61%	-2,592.94%	-1,973.87%
Free Cash Flow to Firm to Interest Expense	1.97	0.00	-0.50	3.68	5.09	1.19	0.42	-5.47	0.00	0.00
Operating Cash Flow to Interest Expense	4.30	0.00	4.85	9.94	4.46	4.59	3.32	-4.83	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	4.03	0.00	4.61	9.03	4.25	4.13	2.51	-5.19	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.68	0.67	0.67	0.60	0.69	0.69	0.50	0.27	0.04	0.06
Accounts Receivable Turnover	5.13	4.78	5.56	6.62	7.37	8.57	10.19	0.00	0.00	0.00
Inventory Turnover	0.71	1.08	0.71	0.49	0.45	0.53	0.82	0.00	0.00	0.00
Fixed Asset Turnover	30.71	29.17	25.40	21.97	24.18	20.80	20.20	18.92	3.09	6.66
Accounts Payable Turnover	0.07	0.10	0.08	0.07	0.07	0.07	0.07	0.03	0.00	0.00
Days Sales Outstanding (DSO)	71.16	76.33	65.65	55.16	49.50	42.61	35.81	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	513.68	337.42	516.03	746.59	818.54	694.59	442.77	0.00	0.00	0.00
Days Payable Outstanding (DPO)	4,886.71	3,661.03	4,510.58	5,034.70	5,601.49	5,615.01	5,210.45	11,599.37	0.00	0.00
Cash Conversion Cycle (CCC)	-4,301.86	-3,247.28	-3,928.90	-4,232.95	-4,733.44	-4,877.81	-4,731.87	-11,599.37	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	649	521	589	373	378	16	-3.16	-26	-41	-42
Invested Capital Turnover	4.02	3.40	3.10	3.02	5.31	119.02	-30.91	-4.83	-0.36	-0.57
Increase / (Decrease) in Invested Capital	128	-67	215	-4.40	361	20	23	15	1.17	-15
Enterprise Value (EV)	11,880	11,235	10,363	7,079	8,207	9,282	5,997	6,473	3,011	4,414
Market Capitalization	13,820	12,946	11,482	8,080	8,955	9,899	6,476	6,866	3,362	4,876
Book Value per Share	$25.58	$22.72	$17.76	$14.48	$12.05	$6.92	$5.30	$4.21	$3.62	$4.92
Tangible Book Value per Share	$25.22	$22.36	$17.38	$14.48	$12.05	$6.92	$5.30	$4.21	$3.62	$4.92
Total Capital	2,590	2,402	1,877	1,709	1,444	1,046	869	742	315	424
Total Debt	0.00	170	169	335	318	409	388	370	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	335	318	0.00	388	370	0.00	0.00
Net Debt	-1,940	-1,711	-1,119	-1,001	-748	-617	-478	-394	-351	-462
Capital Expenditures (CapEx)	38	28	17	23	11	15	25	6.93	4.10	1.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)	141	91	96	16	29	4.00	-1.37	-15	-27	-21
Debt-free Net Working Capital (DFNWC)	1,217	1,122	1,085	727	830	675	650	500	280	358
Net Working Capital (NWC)	1,217	952	916	727	830	266	650	500	280	358
Net Nonoperating Expense (NNE)	59	-61	25	0.97	215	21	15	51	38	23
Net Nonoperating Obligations (NNO)	-1,940	-1,711	-1,119	-1,001	-748	-621	-484	-398	-356	-466
Total Depreciation and Amortization (D&A)	0.90	3.00	19	36	30	28	23	16	4.97	7.04
Debt-free, Cash-free Net Working Capital to Revenue	5.98%	4.81%	6.44%	1.39%	2.74%	0.51%	-0.30%	-9.55%	-182.15%	-105.38%
Debt-free Net Working Capital to Revenue	51.67%	59.47%	72.90%	64.14%	79.33%	85.59%	143.96%	309.66%	1,866.85%	1,812.73%
Net Working Capital to Revenue	51.67%	50.46%	61.52%	64.14%	79.33%	33.71%	143.96%	309.66%	1,866.85%	1,812.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.40	$2.56	$1.61	$0.95	$4.38	$0.40	$0.23	($1.62)	($1.63)	($1.05)
Adjusted Weighted Average Basic Shares Outstanding	100.40M	97.70M	95.80M	94.60M	93.10M	91.63M	90.24M	88.09M	86.71M	84.50M
Adjusted Diluted Earnings per Share	$3.29	$2.47	$1.56	$0.92	$4.16	$0.39	$0.22	($1.62)	($1.63)	($1.05)
Adjusted Weighted Average Diluted Shares Outstanding	103.70M	101M	98.90M	97.90M	97.80M	95.73M	95.39M	88.09M	86.71M	84.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.40	$0.23	($1.62)	$0.00	($1.05)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	99.70M	99.51M	96.59M	95.24M	93.94M	92.29M	90.82M	89.27M	87.11M	86.45M
Normalized Net Operating Profit after Tax (NOPAT)	401	189	180	91	114	58	36	-92	-103	-66
Normalized NOPAT Margin	17.01%	10.00%	12.08%	7.99%	10.91%	7.30%	7.89%	-56.89%	-687.74%	-333.56%
Pre Tax Income Margin	20.63%	17.60%	14.37%	8.95%	10.20%	5.90%	4.83%	-88.19%	-940.60%	-449.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.85	0.00	4.00	4.78	2.84	1.85	1.21	-6.73	0.00	0.00
NOPAT to Interest Expense	2.89	0.00	2.57	3.51	12.15	1.80	1.17	-4.71	0.00	0.00
EBIT Less CapEx to Interest Expense	3.58	0.00	3.76	3.88	2.63	1.39	0.39	-7.08	0.00	0.00
NOPAT Less CapEx to Interest Expense	2.62	0.00	2.33	2.60	11.94	1.34	0.35	-5.07	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	87.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Neurocrine Biosciences' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	11.12%	21.84%	24.72%	30.37%	22.57%	25.05%	28.59%	19.70%	35.35%	32.05%	31.05%
EBITDA Growth	-104.00%	28.88%	65.90%	12.22%	110.36%	51.83%	-2.42%	117.25%	-508.61%	1,605.80%	137.01%
EBIT Growth	-106.94%	27.61%	65.08%	13.17%	110.89%	62.12%	2.22%	134.46%	-586.96%	1,500.00%	172.45%
NOPAT Growth	-89.85%	-19.61%	23.51%	65.83%	256.26%	43.50%	65.22%	50.96%	-4,070.10%	407.18%	87.14%
Net Income Growth	-81.80%	-30.20%	56.20%	-31.94%	156.66%	65.96%	21.31%	665.09%	-651.08%	1,319.18%	204.44%
EPS Growth	-80.95%	-32.89%	51.22%	-33.68%	153.16%	63.74%	18.84%	627.78%	-664.29%	1,400.00%	200.00%
Operating Cash Flow Growth	-50.27%	96.36%	-25.47%	-64.03%	204.07%	-13.64%	114.57%	30.05%	-209.14%	3,304.76%	59.87%
Free Cash Flow Firm Growth	-158.13%	-121.27%	-12.33%	68.84%	274.83%	230.91%	124.19%	31.91%	-16.69%	-552.29%	52.85%
Invested Capital Growth	57.16%	24.60%	15.77%	18.35%	-39.23%	-11.45%	12.76%	30.53%	26.99%	57.61%	52.52%
Revenue Q/Q Growth	-8.78%	0.90%	5.40%	14.54%	0.02%	3.29%	10.18%	7.68%	2.04%	6.21%	2.56%
EBITDA Q/Q Growth	-101.74%	37.99%	32.67%	1,013.27%	-93.23%	77.63%	-10.26%	202.75%	-191.76%	14.16%	99.81%
EBIT Q/Q Growth	-103.06%	37.09%	32.99%	928.69%	-93.20%	77.35%	-8.84%	199.02%	-201.27%	11.83%	109.09%
NOPAT Q/Q Growth	-85.91%	-28.18%	30.79%	-23.27%	11.53%	10.35%	75.60%	172.31%	-202.42%	27.06%	60.44%
Net Income Q/Q Growth	-92.34%	-20.57%	99.69%	49.77%	-70.62%	77.74%	-12.98%	224.67%	-186.07%	29.93%	505.33%
EPS Q/Q Growth	-92.00%	-19.35%	96.83%	50.00%	-71.81%	81.71%	-13.68%	220.25%	-186.81%	31.88%	483.33%
Operating Cash Flow Q/Q Growth	-73.28%	53.48%	144.58%	-50.42%	5.51%	-41.75%	18.04%	243.45%	-187.55%	44.74%	-28.46%
Free Cash Flow Firm Q/Q Growth	-517.41%	-239.96%	182.01%	-108.20%	125.92%	476.81%	129.15%	53.98%	-69.17%	-6.59%	17.96%
Invested Capital Q/Q Growth	5.14%	-9.86%	-13.48%	91.64%	-16.64%	-16.25%	-11.54%	-1.59%	21.46%	6.65%	2.39%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.39%	98.52%	98.71%	98.44%	98.54%	98.35%	97.75%	97.46%	97.98%	98.13%	98.43%
EBITDA Margin	-0.70%	36.69%	26.83%	21.31%	2.19%	34.69%	20.17%	24.76%	-25.95%	28.57%	26.58%
Operating Margin	4.12%	22.62%	29.55%	24.64%	19.27%	29.17%	28.31%	16.26%	-27.16%	25.10%	22.63%
EBIT Margin	-1.22%	36.45%	26.83%	21.26%	2.37%	34.80%	20.27%	24.50%	-26.64%	26.84%	25.50%
Profit (Net Income) Margin	1.38%	16.43%	20.86%	11.01%	8.42%	28.67%	16.66%	21.10%	-18.22%	21.60%	17.66%
Tax Burden Percent	53.74%	63.41%	68.21%	65.92%	125.80%	74.52%	71.89%	78.54%	74.15%	75.49%	69.97%
Interest Burden Percent	-210.00%	71.07%	114.02%	78.57%	282.79%	110.54%	114.34%	109.65%	92.23%	106.60%	98.99%
Effective Tax Rate	46.26%	36.59%	31.79%	34.08%	-25.80%	25.48%	28.11%	21.46%	0.00%	24.51%	30.03%
Return on Invested Capital (ROIC)	9.57%	57.73%	67.33%	44.82%	83.62%	73.95%	61.84%	34.39%	-47.58%	58.64%	48.15%
ROIC Less NNEP Spread (ROIC-NNEP)	9.82%	57.02%	67.07%	47.01%	89.20%	71.42%	63.39%	30.68%	-47.95%	57.61%	47.43%
Return on Net Nonoperating Assets (RNNOA)	-7.59%	-43.18%	-48.00%	-30.46%	-64.02%	-51.31%	-42.41%	-19.05%	28.03%	-39.63%	-32.44%
Return on Equity (ROE)	1.98%	14.56%	19.34%	14.37%	19.60%	22.64%	19.43%	15.34%	-19.55%	19.01%	15.71%
Cash Return on Invested Capital (CROIC)	13.65%	46.56%	49.18%	36.18%	112.39%	46.15%	14.37%	-8.21%	-8.99%	-7.33%	-24.65%
Operating Return on Assets (OROA)	-0.82%	24.63%	18.85%	15.23%	1.61%	23.37%	14.49%	17.75%	-18.91%	18.00%	17.02%
Return on Assets (ROA)	0.93%	11.10%	14.66%	7.89%	5.72%	19.25%	11.91%	15.28%	-12.93%	14.48%	11.79%
Return on Common Equity (ROCE)	1.98%	14.56%	19.34%	14.37%	19.60%	22.64%	19.43%	15.34%	-19.55%	19.01%	15.71%
Return on Equity Simple (ROE_SIMPLE)	12.06%	0.00%	14.19%	13.52%	15.49%	0.00%	9.54%	9.52%	3.80%	0.00%	3.77%
Net Operating Profit after Tax (NOPAT)	13	90	125	96	125	112	102	58	-80	78	61
NOPAT Margin	2.22%	14.34%	20.15%	16.24%	24.24%	21.74%	20.35%	12.77%	-19.02%	18.95%	15.84%
Net Nonoperating Expense Percent (NNEP)	-0.25%	0.72%	0.26%	-2.18%	-5.58%	2.52%	-1.55%	3.71%	0.37%	1.03%	0.71%
Return On Investment Capital (ROIC_SIMPLE)	0.50%	3.48%	-	-	-	4.66%	-	-	-	4.16%	-
Cost of Revenue to Revenue	1.61%	1.48%	1.29%	1.56%	1.46%	1.65%	2.25%	2.54%	2.02%	1.87%	1.57%
SG&A Expenses to Revenue	48.29%	45.85%	37.66%	41.00%	47.18%	42.49%	40.94%	48.99%	57.73%	44.39%	48.03%
R&D to Revenue	45.98%	30.05%	31.51%	32.80%	32.10%	26.69%	28.51%	32.21%	67.41%	28.64%	27.76%
Operating Expenses to Revenue	94.27%	75.90%	69.17%	73.81%	79.27%	69.18%	69.45%	81.20%	125.14%	73.03%	75.79%
Earnings before Interest and Taxes (EBIT)	-7.00	229	167	126	12	179	101	111	-112	111	99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.00	230	167	126	11	179	101	112	-109	118	103
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.35	5.34	4.28	5.52	5.68	5.80	5.49	4.97	5.80	6.72	6.58
Price to Tangible Book Value (P/TBV)	4.41	5.41	4.33	5.60	5.76	5.89	5.58	5.07	5.93	6.87	6.58
Price to Revenue (P/Rev)	4.57	5.87	5.19	6.54	6.84	6.86	6.16	5.50	6.12	7.71	7.31
Price to Earnings (P/E)	36.06	40.49	30.15	40.85	36.65	51.84	57.52	52.16	152.76	74.32	174.53
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.77%	2.47%	3.32%	2.45%	2.73%	1.93%	1.74%	1.92%	0.65%	1.35%	0.57%
Enterprise Value to Invested Capital (EV/IC)	13.44	18.30	13.38	14.63	26.70	21.56	15.44	11.45	12.32	17.61	16.61
Enterprise Value to Revenue (EV/Rev)	3.80	5.04	4.30	5.75	5.85	5.95	5.38	4.81	5.51	6.96	6.60
Enterprise Value to EBITDA (EV/EBITDA)	21.32	22.23	19.93	29.20	28.75	39.80	43.17	35.79	53.54	34.65	48.67
Enterprise Value to EBIT (EV/EBIT)	21.56	22.27	19.91	29.13	28.75	40.22	45.61	38.64	60.82	37.04	56.82
Enterprise Value to NOPAT (EV/NOPAT)	28.27	29.65	22.50	29.92	31.75	59.55	62.08	70.95	93.20	57.62	118.43
Enterprise Value to Operating Cash Flow (EV/OCF)	17.31	19.95	20.23	22.96	17.97	28.81	23.46	27.18	34.58	30.53	45.69
Enterprise Value to Free Cash Flow (EV/FCFF)	120.30	43.61	29.19	43.82	17.96	43.88	113.89	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.05	0.08	0.08	0.09	0.10	0.10	0.11
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.00	0.00
Financial Leverage	-0.77	-0.76	-0.72	-0.65	-0.72	-0.72	-0.67	-0.62	-0.58	-0.69	-0.68
Leverage Ratio	1.45	1.45	1.35	1.36	1.43	1.43	1.41	1.41	1.46	1.44	1.44
Compound Leverage Factor	-3.06	1.03	1.54	1.07	4.05	1.58	1.61	1.55	1.35	1.54	1.42
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	4.89%	7.08%	7.82%	8.39%	9.14%	9.02%	9.87%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	4.89%	7.08%	7.82%	8.39%	0.00%	9.02%	9.87%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.14%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	95.11%	92.92%	92.18%	91.61%	90.86%	90.98%	90.13%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.30	0.60	0.76	0.75	1.03	0.57	0.90
Net Debt to EBITDA	0.00	0.00	0.00	0.00	-4.84	-6.06	-6.20	-5.11	-5.89	-3.74	-5.27
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.03	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.34	0.90	1.10	1.50	1.79	0.94	2.19
Net Debt to NOPAT	0.00	0.00	0.00	0.00	-5.34	-9.07	-8.92	-10.13	-10.26	-6.22	-12.83
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.79	0.00	0.00
Altman Z-Score	6.75	8.58	9.87	11.65	8.40	8.67	8.79	8.26	9.46	11.43	11.06
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.13	3.40	4.37	4.19	2.52	2.45	2.39	2.57	3.83	2.70	2.49
Quick Ratio	2.79	3.06	3.98	3.78	2.33	2.25	2.19	2.34	3.44	2.49	2.27
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-236	-38	27	-33	405	179	31	-107	-232	-137	-129
Operating Cash Flow to CapEx	605.61%	3,321.92%	1,950.62%	556.90%	1,163.39%	2,287.04%	2,789.47%	2,641.18%	-1,472.94%	7,944.44%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-0.44	0.00	-0.67	368.47	0.00	0.00	0.00	-210.76	0.00	-107.14
Operating Cash Flow to Interest Expense	0.00	2.77	0.00	1.30	118.45	0.00	0.00	0.00	-113.82	0.00	82.33
Operating Cash Flow Less CapEx to Interest Expense	0.00	2.68	0.00	1.07	108.27	0.00	0.00	0.00	-121.55	0.00	83.75
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.67	0.68	0.70	0.72	0.68	0.67	0.71	0.72	0.71	0.67	0.67
Accounts Receivable Turnover	4.99	5.13	4.99	4.95	4.71	4.78	4.96	5.02	4.88	5.56	5.97
Inventory Turnover	0.74	0.71	0.89	0.98	1.10	1.08	1.18	1.11	0.87	0.71	0.63
Fixed Asset Turnover	29.73	30.71	30.15	29.09	28.70	29.17	27.51	25.27	25.23	25.40	24.80
Accounts Payable Turnover	0.08	0.07	0.07	0.10	0.10	0.10	0.10	0.10	0.09	0.08	0.08
Days Sales Outstanding (DSO)	73.13	71.16	73.14	73.69	77.56	76.33	73.56	72.72	74.79	65.65	61.11
Days Inventory Outstanding (DIO)	492.29	513.68	410.08	372.02	332.93	337.42	308.70	329.36	420.22	516.03	581.95
Days Payable Outstanding (DPO)	4,561.99	4,886.71	4,923.65	3,760.80	3,644.81	3,661.03	3,756.97	3,549.03	3,984.02	4,510.58	4,690.06
Cash Conversion Cycle (CCC)	-3,996.57	-4,301.86	-4,440.43	-3,315.10	-3,234.32	-3,247.28	-3,374.71	-3,146.95	-3,489.01	-3,928.90	-4,047.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	683	649	720	833	434	521	622	703	715	589	552
Invested Capital Turnover	4.32	4.02	3.34	2.76	3.45	3.40	3.04	2.69	2.50	3.10	3.04
Increase / (Decrease) in Invested Capital	248	128	98	129	-280	-67	70	165	152	215	190
Enterprise Value (EV)	9,174	11,880	9,636	12,178	11,599	11,235	9,606	8,052	8,807	10,363	9,165
Market Capitalization	11,027	13,820	11,634	13,855	13,551	12,946	10,986	9,201	9,777	11,482	10,158
Book Value per Share	$25.43	$25.58	$26.93	$24.93	$23.91	$22.72	$20.50	$18.99	$17.44	$17.76	$16.15
Tangible Book Value per Share	$25.07	$25.22	$26.58	$24.60	$23.57	$22.36	$20.14	$18.61	$17.05	$17.38	$16.15
Total Capital	2,536	2,590	2,719	2,509	2,509	2,402	2,172	2,023	1,854	1,877	1,714
Total Debt	0.00	0.00	0.00	0.00	123	170	170	170	170	169	169
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	170	0.00	0.00
Net Debt	-1,853	-1,940	-1,999	-1,677	-1,952	-1,711	-1,380	-1,150	-970	-1,119	-993
Capital Expenditures (CapEx)	11	7.30	8.10	12	11	5.40	7.60	6.80	8.50	1.80	-1.70
Debt-free, Cash-free Net Working Capital (DFCFNWC)	172	141	219	232	-1.70	91	33	107	164	96	90
Debt-free Net Working Capital (DFNWC)	1,115	1,217	1,447	1,271	1,209	1,122	1,128	1,084	1,059	1,085	890
Net Working Capital (NWC)	1,115	1,217	1,447	1,271	1,086	952	958	914	1,059	916	720
Net Nonoperating Expense (NNE)	4.78	-13	-4.43	31	82	-36	18	-38	-3.34	-11	-7.07
Net Nonoperating Obligations (NNO)	-1,853	-1,940	-1,999	-1,677	-1,952	-1,711	-1,380	-1,150	-970	-1,119	-993
Total Depreciation and Amortization (D&A)	3.00	1.50	0.00	0.30	-0.90	-0.60	-0.50	1.20	2.90	7.10	4.20
Debt-free, Cash-free Net Working Capital to Revenue	7.11%	5.98%	9.76%	10.96%	-0.09%	4.81%	1.86%	6.40%	10.27%	6.44%	6.50%
Debt-free Net Working Capital to Revenue	46.22%	51.67%	64.51%	59.98%	60.99%	59.47%	63.24%	64.78%	66.23%	72.90%	64.06%
Net Working Capital to Revenue	46.22%	51.67%	64.51%	59.98%	54.80%	50.46%	53.72%	54.64%	66.23%	61.52%	51.88%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.08	$1.05	$1.28	$0.64	$0.43	$1.52	$0.85	$0.98	($0.79)	$0.92	$0.72
Adjusted Weighted Average Basic Shares Outstanding	99.70M	100.40M	101.10M	100.80M	99.80M	97.70M	97.90M	97.60M	97.10M	95.80M	95.80M
Adjusted Diluted Earnings per Share	$0.08	$1.00	$1.24	$0.63	$0.42	$1.49	$0.82	$0.95	($0.79)	$0.91	$0.69
Adjusted Weighted Average Diluted Shares Outstanding	102.50M	103.70M	104.30M	103.90M	103.60M	101M	101.10M	100.20M	97.10M	98.90M	99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	98.97M	99.70M	101.25M	100.98M	100.64M	99.51M	98.25M	97.65M	97.57M	96.59M	96.13M
Normalized Net Operating Profit after Tax (NOPAT)	13	90	125	96	70	112	102	58	-80	78	61
Normalized NOPAT Margin	2.22%	14.34%	20.15%	16.24%	13.49%	21.74%	20.35%	12.77%	-19.02%	18.95%	15.84%
Pre Tax Income Margin	2.57%	25.90%	30.59%	16.71%	6.70%	38.47%	23.18%	26.86%	-24.57%	28.62%	25.24%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	2.61	0.00	2.53	11.09	0.00	0.00	0.00	-101.82	0.00	82.42
NOPAT to Interest Expense	0.00	1.03	0.00	1.93	113.56	0.00	0.00	0.00	-72.67	0.00	51.19
EBIT Less CapEx to Interest Expense	0.00	2.53	0.00	2.29	0.91	0.00	0.00	0.00	-109.55	0.00	83.83
NOPAT Less CapEx to Interest Expense	0.00	0.94	0.00	1.70	103.38	0.00	0.00	0.00	-80.40	0.00	52.61
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	147.16%	87.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Neurocrine Biosciences' Financials

When does Neurocrine Biosciences's fiscal year end?

According to the most recent income statement we have on file, Neurocrine Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Neurocrine Biosciences' net income changed over the last 9 years?

Neurocrine Biosciences' net income appears to be on an upward trend, with a most recent value of $341.30 million in 2024, falling from -$88.93 million in 2015. The previous period was $249.70 million in 2023. View Neurocrine Biosciences' forecast to see where analysts expect Neurocrine Biosciences to go next.

What is Neurocrine Biosciences's operating income?

Neurocrine Biosciences's total operating income in 2024 was $570.50 million, based on the following breakdown:

Total Gross Profit: $2.32 billion
Total Operating Expenses: $1.75 billion

How has Neurocrine Biosciences revenue changed over the last 9 years?

Over the last 9 years, Neurocrine Biosciences' total revenue changed from $19.77 million in 2015 to $2.36 billion in 2024, a change of 11,814.1%.

How much debt does Neurocrine Biosciences have?

Neurocrine Biosciences' total liabilities were at $1.13 billion at the end of 2024, a 10.8% increase from 2023, and a 2,143.2% increase since 2015.

How much cash does Neurocrine Biosciences have?

In the past 9 years, Neurocrine Biosciences' cash and equivalents has ranged from $74.20 million in 2015 to $340.80 million in 2021, and is currently $233 million as of their latest financial filing in 2024.

How has Neurocrine Biosciences' book value per share changed over the last 9 years?

Over the last 9 years, Neurocrine Biosciences' book value per share changed from 4.92 in 2015 to 25.58 in 2024, a change of 419.4%.

Related Companies

This page (NASDAQ:NBIX) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurocrine Biosciences (NBIX) Financials

Frequently Asked Questions About Neurocrine Biosciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurocrine Biosciences (NBIX) Financials

Annual Income Statements for Neurocrine Biosciences

Quarterly Income Statements for Neurocrine Biosciences

Annual Cash Flow Statements for Neurocrine Biosciences

Quarterly Cash Flow Statements for Neurocrine Biosciences

Annual Balance Sheets for Neurocrine Biosciences

Quarterly Balance Sheets for Neurocrine Biosciences

Annual Metrics And Ratios for Neurocrine Biosciences

Quarterly Metrics And Ratios for Neurocrine Biosciences

Frequently Asked Questions About Neurocrine Biosciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools